FEROZ · Ferozsons Laboratories Limited
Material Information
- Filed
- 17 September 2026 at 8:04 am
- Category
- Material
- Sentiment
- Good
- Impact
- High
AI executive summary
Ferozons Laboratories Limited has entered into a royalty-free voluntary licensing agreement with Gilead for the manufacture and sale of lenacapavir for HIV prevention in 120 low- and lower-middle-income countries. The agreement covers technology transfer and manufacturing readiness, with the injectable variant to be produced by its JV subsidiary BF Biosciences and the oral variant by Ferozons directly.
Key takeaways
- Entered royalty-free voluntary licensing agreement with Gilead for lenacapavir
- Covers 120 low- and lower-middle-income countries for HIV prevention
- Includes technology transfer and manufacturing readiness
- Injectable to be manufactured via JV subsidiary BF Biosciences and oral variant by Ferozons
- #licensing
- #partnership
- #gilead
- #hiv
- #manufacturing
This summary is AI-generated and may contain errors or omissions. Review the official PSX filing before making an investment decision.